Cadila-Hetero Slugfest Over The 'Hep' Tag
Trademark disputes continue unabated in Indian courts, this time involving generic versions of Bristol-Myers Squibb's hepatitis C therapy, Daklinza (daclatasvir) marketed by the local firms Cadila Healthcare and Hetero.
You may also be interested in...
Gilead Sciences has moved court to block an alleged copy of its blockbuster hepatitis C treatment, Harvoni (sofosbuvir/ledipasvir), in India which it believes not only wrongly rides on the brand name but may also not have the requisite regulatory approvals.
The licensing agreement announced on Nov. 23 by the Medicines Patent Pool and Bristol-Myers Squibb, under which generics firms will be able to manufacture their own versions of the firm's hepatitis C drug daclatasvir for sale in more than a hundred lower-income countries, breaks new ground in several different ways.
Novartis and Intas Pharmaceuticals Ltd have reached an out-of-court settlement pertaining to their dispute concerning ranibizumab.